331
Participants
Start Date
November 23, 2006
Primary Completion Date
July 31, 2009
Study Completion Date
July 26, 2024
ZD6474 (Vandetanib)
once daily oral tablet
Investigational Site Number 1101, Brussels
Investigational Site Number : 1101, Anderlecht
Investigational Site Number 1901, Vienna
Investigational Site Number : 1901, Vienna
Investigational Site Number 1001, St Leonards
Investigational Site Number 1102, Leuven
Investigational Site Number : 1102, Leuven
Investigational Site Number 2101, Basel
Investigational Site Number : 2101, Basel
Investigational Site Number 2701, Odense C
Investigational Site Number : 2701, Odense C
Investigational Site Number 1601, Pécs
Investigational Site Number : 1601, Pécs
Investigational Site Number 3401, Belgrade
Investigational Site Number : 3401, Belgrade
Investigational Site Number 2402, Mexico City
Investigational Site Number 3601, Prague
Investigational Site Number : 3601, Prague
Investigational Site Number 3102, Stockholm
Investigational Site Number : 3102, Stockholm
Investigational Site Number 3003, Madrid
Investigational Site Number : 3003, Madrid
Investigational Site Number 3001, Madrid
Investigational Site Number : 3001, Madrid
Investigational Site Number 19, Charleston
Medical University of South Carolina- Site Number : 19, Charleston
Investigational Site Number : 3002, Pamplona
Investigational Site Number 3002, Pamplona
Investigational Site Number 15, Jacksonville
Mayo Clinic- Site Number : 15, Jacksonville
Investigational Site Number 2802, Bordeaux
Investigational Site Number : 2802, Bordeaux
Investigational Site Number 2002, Essen
Investigational Site Number : 2002, Essen
Investigational Site Number 7, Detroit
Wayne State University / Harper Hospital Site Number : 7, Detroit
Investigational Site Number 2504, Siena
Investigational Site Number : 2504, Siena
Investigational Site Number 14, Rochester
Mayo Clinic- Site Number : 14, Rochester
Investigational Site Number 2501, Pisa
Investigational Site Number : 2501, Pisa
Investigational Site Number 18, Chicago
The University Of Chicago Site Number : 18, Chicago
Investigational Site Number 10, St Louis
Washington University School Of Med Site Number : 10, St Louis
Investigational Site Number 2803, Lyon
Investigational Site Number : 2803, Lyon
Investigational Site Number 3, Little Rock
University Arkansas Site Number : 3, Little Rock
Investigational Site Number 3101, Uppsala
Investigational Site Number : 3101, Uppsala
Anderson Cancer Center Site Number : 13, Houston
Investigational Site Number 13, Houston
Investigational Site Number 9, Aurora
University Of Colorado Health Sciences Center Site Number : 9, Aurora
Investigational Site Number 2503, Napoli
Investigational Site Number : 2503, Napoli
Investigational Site Number 8, San Francisco
USCF / Mt Zion Medical Center Site Number : 8, San Francisco
Investigational Site Number 2801, Villejuif
Investigational Site Number : 2801, Villejuif
Investigational Site Number 2005, Würzburg
Investigational Site Number : 2005, Würzburg
Investigational Site Number 22, Portland
Oregon Health & Science University- Site Number : 22, Portland
Investigational Site Number 3301, Obninsk
Investigational Site Number : 3301, Obninsk
Investigational Site Number 1401, Mumbai
Investigational Site Number : 1401, Mumbai
Investigational Site Number 1402, Vellore
Investigational Site Number : 1402, Vellore
Investigational Site Number 11, New Haven
Yale University School Medicine Site Number : 11, New Haven
Investigational Site Number 17, Lexington
The University Of Kentucky Site Number : 17, Lexington
Dana Farber Cancer Institute Site Number : 2, Boston
Investigational Site Number 2, Boston
Investigational Site Number 6, Cincinnati
University Of Cincinnati Site Number : 6, Cincinnati
Fletcher Allen Health Care Site Number : 21, Burlington
Investigational Site Number 21, Burlington
Hospital De Clinicas De Porto Alegre- Site Number : 2301, Porto Alegre
Investigational Site Number 2301, Porto Alegre
Faculdade de Medicina de Ribeirao Preto - USP- Site Number : 2302, Ribeirão Preto
Investigational Site Number 2302, Ribeirão Preto
Investigational Site Number : 1203, Calgary
Investigational Site Number 1203, Calgary
Investigational Site Number : 1201, Moncton
Investigational Site Number 1201, Moncton
Investigational Site Number : 1202, London
Investigational Site Number 1202, London
Investigational Site Number : 1205, Toronto
Investigational Site Number 1205, Toronto
Investigational Site Number : 1204, Sherbrooke
Investigational Site Number 1204, Sherbrooke
Investigational Site Number 2001, Halle
Investigational Site Number : 2001, Halle
Investigational Site Number 2506, Catania
Investigational Site Number : 2506, Catania
Investigational Site Number 2502, Milan
Investigational Site Number : 2502, Milan
Investigational Site Number 2403, Ciudad Madero
Investigational Site Number 2902, Groningen
Investigational Site Number : 2902, Groningen
Investigational Site Number 2901, Utrecht
Investigational Site Number : 2901, Utrecht
Investigational Site Number 1801, Bucharest
Investigational Site Number 3402, Belgrade
Investigational Site Number : 3402, Belgrade
Investigational Site Number 1501, Seoul
Investigational Site Number 2505, Roma
Investigational Site Number : 2505, Roma
Investigational Site Number 2404, México
Investigational Site Number : 2404, México
Investigational Site Number : 1702, Poznan
Investigational Site Number 1702, Poznan
Investigational Site Number : 1703, Warsaw
Investigational Site Number 1703, Warsaw
Investigational Site Number 1701, Gliwice
Investigational Site Number : 1701, Gliwice
Investigational Site Number 2602, Coimbra
Investigational Site Number 2601, Lisbon
Investigational Site Number : 2601, Lisbon
Investigational Site Number : 1501, Seoul
Investigational Site Number 2102, Bern
Investigational Site Number : 2102, Bern
Genzyme, a Sanofi Company
INDUSTRY